GlassScriptPhysician profile
Willie Hamilton
NPI 1164433587
$5,563.17
in general payments reported to CMS, 2019-2025
13 companies · $54.15 in 2025
The $54.15 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $497 · 2023: $4,254 · 2024: $614 · 2025: $54.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,940 · Travel and Lodging: $1,677 · Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,940.00 |
| Travel and Lodging | $1,676.87 |
| Food and Beverage | $1,304.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,387.15 | 2022-2025 | Epclusa, Livdelzi |
| Novo Nordisk INC | $381.60 | 2021-2024 | Wegovy |
| Abbvie INC. | $132.42 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.14 | 2022-2024 | Caplyta |
| Indivior INC. | $110.52 | 2022-2024 | Sublocade |
| Lundbeck LLC | $77.81 | 2024 | Vyepti |
| Neurocrine Biosciences, INC. | $73.08 | 2021 | |
| Amgen INC. | $72.39 | 2022 | |
| Braeburn INC. | $66.68 | 2023-2024 | Brixadi |
| Sanofi-Aventis U.S. LLC | $62.03 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $50.18 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.43 | 2024 | Invega Sustenna |
| Axsome Therapeutics, INC. | $18.74 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willie Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.